Wednesday, April 17, 2024
HomeFunding PA-based Prolocor Secures $1.7Million in Bridge Funding

[Funding alert] PA-based Prolocor Secures $1.7Million in Bridge Funding

PA-based Prolocor secures $1.7million in bridge funding. The financing included significant participation by Green Park & Golf Ventures (GPG Ventures) and by the Labcorp Venture Fund.

PA-based Prolocor secures $1.7million in bridge funding. The financing included significant participation by Green Park & Golf Ventures (GPG Ventures) and by the Labcorp Venture Fund.

Read also – WA-based Gradial Secures $5.4Million in Seed Funding

Dr. Clay Heighten, Managing Partner at GPG Ventures, remarked, “We are encouraged by the impressive progress that the team at Prolocor is making. We look forward to the continued development of this important marker and the results of their ongoing clinical trials.”

Dr. Peter DiBattiste, Co-Founder and CEO of Prolocor shared, “We have completed the enrollment of our 800 patient acute coronary syndrome (ACS) trial at 25 nationally recognized hospitals and completed an interim analysis of this confirmatory study in September 2023. In addition, our Co-Founder and CSO Dr. David Schneider and his lab team have confirmed the precision, accuracy, and specificity of the unique pCFG test. We sincerely appreciate GPG Ventures and Labcorp’s ongoing support.”

Megann Vaughn Watters, Vice President, New Venture & Strategic Alliances, Labcorp said, “We are very excited about the advancement being made by the Prolocor team and the important work they are doing to advance their innovative test to help predict risk of thrombosis,”

Co-Founder and CSO Dr. David Schneider said, “The Prolocor pFCG test provides powerful prognostic information leveraging a novel approach. The test is performed on fixed platelets removing a major technical limitation of platelet assays,”.

There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over two million suffer from acute coronary syndrome every year.

In each case, the doctor and patient must decide whether to use more powerful therapy to reduce the risk of thrombosis — increasing the risk of bleeding — or less-intensive therapy — reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular-related death.

Read also – OH-based Relish Secures $10Million in Series A Round Funding

About Procolor

Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular